Floatz logo

PROPADERM FORTE

Graft Versus Host Disease

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Graft Versus Host Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 4BBB
Busulphan
City of Hope Medical Center
Phase 4BBB
Thiotepa
Memorial Sloan Kettering Cancer Center
Phase 4BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

PROPADERM FORTE is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
58 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →